2025
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Yates S, Weiss J, Sneider A, Geramita E, Murthy G, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer E, Litzow M, Atallah E, Patel A, Shallis R. Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Haematologica 2025 PMID: 40702896, DOI: 10.3324/haematol.2025.288085.Peer-Reviewed Original ResearchTreatment start dateAcute myeloid leukemiaHypomethylating agentsOverall survivalEuropean LeukemiaNetMyeloid leukemiaAML disease biologyDiagnosis of acute myeloid leukemiaAML-directed therapyDiagnosis to initiationRetrospective cohort studyMyeloid malignanciesRisk diseaseSurvival outcomesOncologic emergencyCohort studyAcademic centersMulti-centerNeoplastic diseasePatientsDisease biologyRisk classificationDiagnosisLeukemiaSurvival
2024
Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
Weiss J, Yates S, Badar T, Patel A, Winer E, Litzow M, Cheng W, Lin C, Shallis R. Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax. Blood 2024, 144: 1489-1489. DOI: 10.1182/blood-2024-206670.Peer-Reviewed Original ResearchAcute myeloid leukemiaBody mass indexOverall response rateBody mass index groupsSecondary AMLObese ptsHypomethylating agentsEuropean LeukemiaNetMulti-centerOverall survivalMyeloid leukemiaRetrospective studyMass indexNewly diagnosed acute myeloid leukemiaVariable volume of distributionSecondary acute myeloid leukemiaAssociated with higher 90-day mortalityTreatment of acute myeloid leukemiaHigher 30-day mortalityMultivariate Cox regression modelInterquartile rangeComposite remission rateExtensive protein bindingKaplan-Meier methodRisk of early mortalityImpact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Yates S, Weiss J, Sneider A, Geramita E, Guru Murthy G, Badar T, Im A, Lin C, Cheng W, Winer E, Abaza Y, Litzow M, Atallah E, Swaroop A, Patel A, Shallis R. Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2024, 144: 447-447. DOI: 10.1182/blood-2024-207116.Peer-Reviewed Original ResearchDiagnosed AMLAcute myeloid leukemiaEuropean LeukemiaNetOverall survivalComplete responseECOG PSHypomethylating agentsSeverity of presentationMulti-centerPerformance statusRetrospective analysisFactors associated with improved OSTherapy-related acute myeloid leukemiaECOG PS of 2Initiation of induction therapyMultivariate analysisAssociated with worse OSNext generation sequencing panelIntermediate risk diseaseIncomplete count recoveryECOG performance statusDisease biologyNPM1 mutation statusUnivariate Cox modelPre-planned subgroup analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply